Eli Lilly secures FDA approval for Foundayo, an oral GLP-1 therapy targeting obesity with significant advantages. Learn why LLY stock is a buy.
Foundayo Explained: Lilly’s New Weight Loss Pill And The Amazon Effect

Source: Seeking Alpha
Read Full Story →



